Aleksandar Milosevic

Essen, NW 45141, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Diagnostic Potential of Apparent Diffusion Coefficient-Based Lymph Node Classification in Breast Cancer Patients Undergoing [18F]FDG-PET/MRI.

Diagnostic Potential of Apparent Diffusion Coefficient-Based Lymph Node Classification in Breast Cancer Patients Undergoing [18F]FDG-PET/MRI.

Journal: Diagnostics (Basel, Switzerland)

Published: April 19, 2026

Diagnostic value of integrated 18F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.

Diagnostic value of integrated 18F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.

Journal: Nuclear medicine communications

Published: March 18, 2026

Evaluation of standardized uptake value (SUV) and apparent diffusion coefficient (ADC) as prognostic imaging parameters for primary Ewing sarcoma in hybrid 18F-FDG-PET/MRI.

Evaluation of standardized uptake value (SUV) and apparent diffusion coefficient (ADC) as prognostic imaging parameters for primary Ewing sarcoma in hybrid 18F-FDG-PET/MRI.

Journal: European journal of radiology

Published: January 25, 2026

Imaging of visceral, retroperitoneal, and pelvic soft-tissue sarcomas : Review

Imaging of visceral, retroperitoneal, and pelvic soft-tissue sarcomas : Review

Journal: Radiologie (Heidelberg, Germany)

Published: January 09, 2026

Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer.

Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer.

Journal: Thoracic cancer

Published: August 29, 2025

[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer.

[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 22, 2025

Evaluation of diffusion-weighted imaging datasets for the assessment of disease activity in lymphoma patients.

Evaluation of diffusion-weighted imaging datasets for the assessment of disease activity in lymphoma patients.

Journal: European journal of radiology

Published: March 19, 2025

Liver volumetry improves evaluation of treatment response to hepatic artery infusion chemotherapy in uveal melanoma patients with liver metastases.

Liver volumetry improves evaluation of treatment response to hepatic artery infusion chemotherapy in uveal melanoma patients with liver metastases.

Journal: Radiology and oncology

Published: August 02, 2024

Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI.

Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI.

Journal: Nuclear medicine communications

Published: October 12, 2023

Impact of CT and MRI in the diagnostic workup of malignant triton tumour-a monocentric analysis and review of the literature.

Impact of CT and MRI in the diagnostic workup of malignant triton tumour-a monocentric analysis and review of the literature.

Journal: The British journal of radiology

Published: August 14, 2023

Conventional Imaging, MRI and 18F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast Cancer.

Conventional Imaging, MRI and 18F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast Cancer.

Journal: Cancers

Published: June 14, 2023

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: February 07, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026